Phagenix Progress Report

Both campaigns close Email 2 with "Happy to share the deck." This is a passive, supplicant-position CTA that rewards investor skepticism. Of 15 total replies across both campaigns, zero came from Email 2. Prospects go cold between Email 1 intrigue and Email 3 breakup — Email 2 is where the booking should happen.

AMR investors in 2026 are fatigued by 'send me more info' cycles. Phage has a long history of pre-revenue decks that go nowhere. A hard booking ask cuts through that pattern and forces a binary decision.

• Variant A (Hard): "Worth 20 minutes Thursday or Friday? I can share the Phase 2 data and Q1 EBITDA in one call."
• Variant B (Medium): "Can I send a 3-slide summary — then book 15 minutes if it's relevant?"

The MENA campaign runs a single variant in every step — violating Keller's minimum of 3 structural variants for fingerprint prevention and frame testing. More critically, the MENA Email 1 opener 'The hospitals across MENA deal with this daily' is a hospital sales frame, not an investor frame. MENA family offices and healthcare holding groups already know AMR exists — they need to see a regional commercial path, not an epidemiology reminder.

CE-mark is EU only; phage therapy has no reimbursement pathway in GCC; and any clinical mention triggers regulatory caution that the current copy doesn't preempt.

• Variant B: "Phagenix is the only AMR company with active European hospital contracts and a Phase 2 RCT running simultaneously. Revenue-positive today. The MENA infrastructure angle is a strategic fit for what you build."
• Variant C: "Most phage pitches are burn-rate stories from pre-revenue teams. Phagenix is EBITDA-positive, CE-marked, and running the first global RCT in prosthetic joint infection from July. Different category."

Global campaign's Variant B opens with "ARMATA returned +430% on Phase 2a phage data" and positions Phagenix as the only company with an active PJI RCT globally. This is the most investor-native frame in the entire campaign — it anchors to a real market event and gives the reader a reference point for value creation. Yet MENA never sees it, and in Global it shares equal weight with two weaker variants.

Phage therapy's biggest perception problem in the investor community is 'we've heard this before and nothing exits.' ARMATA's +430% on Phase 2a data is the counter-evidence. APT (the main US competitor) withdrew all PJI programs without enrolling a single patient — Phagenix holds that ground alone.

• Promote ARMATA variant to 50%+ of contact allocation in Global Email 1.
• Add ARMATA frame as the lead variant in MENA Email 1.
• Localize for MENA: "ARMATA returned +430% on phage in the US. The uncontested European position in prosthetic joint infection belongs to Phagenix — EBITDA-positive, Phase 2 starting July 2026."